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Albumin has been implicated in Alzheimer’s disease since it can bind to and transport 
amyloid beta, the causative agent; albumin is also a potent inhibitor of amyloid beta 
polymerization. In a pilot phase study of Human Brain Proteome Project, we found 
evidence that albumin may be synthesized in immortalized human microglial cells, human 
primary microglial cells, and human fetal and adult brain tissues. We also found the 
synthesis and secretion is enhanced upon microglial activation by Aβ1-42, 
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lipopolysaccharide  treatment or human Alzheimer’s brain. 
Albumin is the most abundant plasma protein with multifunctional properties such as 
ligand-binding and transport, maintaining the colloid osmotic pressure of plasma, and regulating 
neutrophil function. Albumin is mainly synthesized in the liver at a rate of ~12 g per day, 
representing ~25% of total hepatic protein synthesis2. Albumin has been implicated in 
Alzheimer’s disease (AD) since it can bind to and transport amyloid beta (A )β 3, the causative 
agent of AD; albumin is also a potent inhibitor of A  polymerizationβ 4. Despite the evidence of 
non-hepatic transcription of albumin in many tissues5,6, non-hepatic synthesis of albumin at the 
protein level has been rarely confirmed. There has been no specific report about the synthesis of 
albumin in brain either at the mRNA level or at the protein level.   
Albumin is not only a high-abundance protein in plasma, but also a major component of 
most extracellular fluids including interstitial fluid, lymph, and cerebrospinal fluid (CSF)7-9 
Albumin is found at a low concentration (~0.2 g/L) in CSF, yet it amounts to  ~80% of the total 
CSF protein in contrast to ~60% as in plasma. CSF serum quotient of albumin, along with other 
blood-derived proteins in CSF, is widely used in the diagnosis of neurological diseases10. 
Albumin has been implicated in AD because it can specifically bind to and transport A , theβ  
causative agent of AD, under physiological conditions. Moreover, albumin is a potent inhibitor 
of A  polymerization, representing ~60% of amyloid inhibitory activity in CSF and plasmaβ 4. 
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To provide evidence of albumin synthesis in human microglial cells, three biospecimens 
were used: 1) immortalized human microglial cell line (HMO6); 2) human primary microglial 
cells; 3) human fetal and adult brain tissues. Additionally, Alzheimer’s brain tissues were used to 
show the increased synthesis of albumin in microglial cells in AD, and all experimental 
procedures were described in Supplementary Methods.
We used immunostaining for albumin and microglial markers in human cells and brain 
tissues to confirm that albumin is expressed in microglial cells both in vitro and in vivo. In 
immunocytochemistry, all HMO6 cells were double-positive for microglial markers (CD11b and 
Iba1) and albumin (Fig. 1a); human primary microglial cells staining positive for Iba1 
coexpressed albumin (Fig. 1b). In immunohistochemical study using human fetal and adult brain 
tissues, cells staining positive for microglial markers (CD11b and Iba1), also coexpressed 
albumin (Fig. 1c&d). When human adult brain tissues were double stained for albumin and non-
microglial cell markers (i.e. microtubule-associated protein 2 (MAP2) for neurons; glial 
fibrillary acidic protein (GFAP) for astrocytes; myelin basic protein (MBP) for 
oligodendrocytes), minimal co-localization was observed (Fig. 1e-g). 
To further confirm that albumin detected in HMO6 cells is not bovine albumin from the 
incubation media but human albumin, peptide sequencing using MS/MS was performed, which 
provided clear evidence that the albumin in HMO6 cells is human origin (Fig. 1h). The list of 
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tryptic peptides identified using MS/MS is summarized in Supplementary Table 1.
Interestingly, the levels of albumin mRNA and protein increased upon microglial activation 
by Aβ1-42 or lipopolysaccharide(LPS) treatments (Fig. 2). According to quantitative real-time 
PCR results, albumin gene transcription in HMO6 cells was more responsive to Aβ1-42 than to 
LPS (Fig. 2a), which did not correlate well with albumin protein synthesis as illustrated by 
immunoblot analysis using HMO6 cell lysates (Fig. 2b). This may be partly explained by the fact 
that albumin is directly secreted from cells after synthesis. In accordance with this explanation, 
the level of albumin secreted by HMO6 cells into the incubation media also increased 
significantly after microglial activation, and was more responsive to Aβ1-42 than LPS (Fig. 2c). 
In Alzheimer’s brain, Iba1 and albumin were mostly co-localized (Fig. 2d).
In summary, we report here, for the first time, the synthesis of albumin in human microglial 
cells, the resident phagocytic cells in brain. Furthermore, our data show that the expression level 
of albumin in microglial cells increases upon activation with Aβ1-42 or LPS treatments. These 
findings provide a new insight into the role of microglial cells in AD in which the ‘amyloid 
hypothesis’ that A  aggregates to trigger a complex pathologic cascade leading toβ  
neurodegeneration is generally accepted11. Microglial cells have been implicated in AD mainly 
because of their markedly elevated distribution in brain regions with A  deposition, and theirβ  
pro-inflammatory functions12. Despite all the circumstantial evidence against microglial 
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involvement in AD, it is still not clear whether microglial cells are ‘friends or foes’ in AD13. Our 
findings suggest that microglial cells may diminish A  deposition by increasing albuminβ  
synthesis and secretion. The capacity to bind to and transport A  enables albumin to inhibitβ  
A  polymerization and to increase A  clearanceβ β 14 . 
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Figure 1. Albumin expression in human microglial cells and representative MS/MS spectra 
of a tryptic peptide of albumin. Microglial markers (CD11b or Iba-1) were co-expressed with 
albumin in all HMO6 cells (a) and human primary microglial cells (b). This observation was 
further confirmed by immunohistochemical staining of human fetal (c) and adult (d) brain 
tissues, in which albumin was co-expressed with CD11b or Iba-1. Minimal co-localization of 
albumin and non-microglial markers was observed in other cell types of brain: MAP2 for 
neurons (e); GFAP for astrocytes (f); MBP for oligodendrocytes (g). Scale bars = 50µm. 
(h) Peptide sequencing provided clear evidence that albumin found in HMO6 cells is not bovine 
but human origin. The peptide QNCELFEQLGEYK is human-specific (i.e. the sequence is not 
100% homologous with its bovine homologue, and thus distinguishable using MS/MS. The list 
of tryptic peptides identified using MS/MS is summarized in Supplementary Table. 
Figure 2. Increase in albumin synthesis and secretion after microglial activation by Aβ1-42, 
LPS treatments or human Alzheimer’s brain tissue. qRT-PCR data (a) show that the 
transcription of albumin gene is significantly enhanced after microglial activation by Aβ1-42 or 
LPS treatment. Immunoblot data also show that albumin synthesis increases at the protein level 
after microglial activation (b). In addition, immunoblot data show that anti-human-albumin 
antibody used does not have any cross-reactivity with bovine albumin in fetal bovine serum 
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(FBS), and that albumin is present in the incubation medium (sup, i.e. thus secreted from cells). 
ELISA data show that albumin secretion from HMO6 cells increased significantly after 
microglial activation (c). Moreover, the level of albumin in the incubation medium of Aβ1-42 
treated cells was significantly higher than that of LPS treated cells. (d) Microglial cells showed 
increased albumin staining intensity and size in human Alzheimer’s brain tissue. Iba1, a 
microglial marker, and albumin were co-localized. Scale bar = 50µm.
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SUPPLEMENTARY METHODS
Cell culture. For in vitro study, immortalized human microglial cell line (HMO6) was used. 
HMO6 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) with high 
glucose supplemented with 10% fetal bovine serum (FBS, Gibco) and 20 g/ml gentamicinμ  
(Sigma), and incubated at 37 °C and 5% CO2. Lipopolysaccharide (LPS) and Aβ1-42 were 
acquired from Sigma-Aldrich and added to HMO6 cells at a concentration of 100 ng/mL and 
5mM, respectively. Either LPS- or Aβ1-42-treated HMO6 cells were harvested 6 hrs after 
treatment for further analysis except ELISA in which the incubation media were collected along 
12 hrs time course for analysis.
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Primary human microglial cell culture. Primary human microglial cells were prepared from 
embryonic human brains of 12-15 weeks gestation. The use of embryonic tissue samples were 
approved by Ethics Committee of the University of British Columbia, Faculty of Medicine. 
Briefly, brain tissues were incubated in phosphate-buffered saline (PBS) containing 0.25% 
trypsin and 40 µg/ml DNase I for 30 min at 37 °C. Dissociated cells were suspended in DMEM 
supplemented with 5% FBS, 5% horse serum, 20 µg/ml gentamicin, and 2.5 µg/ml amphotericine 
B (feeding medium), plated at a density of 106 cells/ml in 10 cm culture dish (10 ml), and 
incubated at 37 °C in an incubator with 5% CO2/95% air atmosphere. After 2-3 weeks in vitro, 
microglia-enriched cultures were prepared by harvesting the floating cells in culture dish and 
replating them on Lab-Tek II Chamber Slide System (2  10ⅹ 4 cells/wells, Nunc) for 
immunocytochemistry.
Immunoblot. Cell lysates were prepared with lysis buffer containing 7M urea, 2M thiourea, and 
4% CHAPS. 2ml of the incubation medium was harvested, centrifuged at 1500 rpm for 10 
minutes, and the supernatant was concentrated to about 15 µl using an Amicon centrifugal filter 
with 10-kDa nominal molecular weight limit (Millipore). Cell lysates, the incubation medium 
concentrate, and FBS were separated in 4-12% polyacrylamide gels (Invitrogen) and transferred 
to nitrocellulose membrane. The primary antibodies used were anti-human-albumin (1:1000, 
Abcam) that does not have cross-reactivity with bovine albumin, and anti-β-actin (1:1000, Cell 
Signaling).
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Quantitative real-time PCR (qRT-PCR). RNA was isolated from six biological replicates from 
each group using Qiagen RNeasy MiniKit (Qiagen), pooled, and subjected to first-strand cDNA 
synthesis using Reverse Transcription System (Promega) according to the manufacturer’s 
protocol.  qRT-PCR was performed using Rotor-Gene 6000 (Corbett Lifescience), threshold 
cycle number and reaction efficiency were determined using Rotor-Gene 6000 series software 
version 2.7, and the 2- CΔΔ T method was used for relative quantitation. The primers used were: 
5’-ATGCCCCGGAACTCCTTTTC-3’ (forward) and 5’-CAACAGGCAGGCAGCTTTAT-3’ 
(reverse) for albumin, and 5’-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3’ (forward) 
and 5’-TGACGGGGTCACCCACACACTGTGCCCATCTA -3’ (reverse) for GAPDH.
Enzyme-Linked Immunosorbent Assay (ELISA). The amount of albumin in the cell 
incubation media was determined by human albumin BioAssay ELISA kit (US Biological). Six 
biological replicates were used, and each replicate was measured in duplicate. 
Immunocytochemistry (ICC) 
Cells were grown on Lab-Tek II chamber slide (Nunc), rinsed in PBS, fixed in 4% 
paraformaldehyde for 20 min, and rinsed again in PBS. The cells were incubated for overnight at 
4 °C with mouse anti-human-albumin antibody (1:200, R&D system) that does not have cross-
reactivity with bovine albumin, rabbit ant-Iba1 antibody (1:200, WAKO pure chemical 
industries) and rabbit ant-CD11b antibody (1:200, Abcam). The cells were rinsed in PBS and 
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incubated for 1 hr at room temperature with tetramethylrhodamine isothiocyanate (TRITC)-
conjugated anti-mouse IgG (1:500, Molecular Probes) and fluorescein isothiocyanate (FITC)-
conjugated anti-rabbit IgG (1:500, Molecular Probes). After wash in PBS, coverslips were 
mounted onto glass slides using Fluoroguard Antifade reagent (Bio-Rad Laboratories), and 
examined under a laser confocal fluorescence microscope (FV500, Olympus).
Immunohistochemistry (IHC)
IHC was performed as previously described. Human fetal (23wks), adult and Alzheimer’s brain 
tissues were acquired from the Brain bank of Seoul National University hospital. The use of 
human brain tissues was approved by the institutional review board of Clinical Research 
Institute, Seoul National University hospital. Briefly, human adult, fetal brain tissues were fixed 
in 4% paraformaldehyde in 0.1 M phosphate buffer, followed by cryoprotection in 30% sucrose 
for overnight, and then 30 µm sections were prepared on a cryostat (Leica CM 1900). Paraffin-
embedded 4 m thick Alzheimer’s brain tissue sections were de-paraffinized in xylene andμ  
rehydrated in a graded ethanol series. Antigen retrieval was performed by immersing slides in 
citrate buffer (pH 6) at 100 °C for 30 min. 10% normal goat serum was used to block non-
specific binding. The tissue sections were incubated for overnight at 4 °C with mouse anti-
albumin (1:100, R&D system), rabbit anti-Iba1 (1:200, WAKO), rabbit anti-CD11b (1:200, 
Abcam), rabbit anti-GFAP (1:200, Chemicon), rabbit anti-MAP2 (1:200, Chemicon) and rabbit 
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anti-MBP (1:200, Chemicon). The tissues were rinsed in PBS and incubated for 1 hr at room 
temperature with TRITC-conjugated anti-mouse IgG (1:500, Molecular Probes) and FITC-
conjugated anti-rabbit IgG (1:500, Molecular Probes). After wash in PBS, coverslips were 
mounted onto glass slides using Fluoroguard Antifade reagent (Bio-Rad Laboratories), and 
examined under a laser confocal fluorescence microscope (FV500, Olympus). 
Immunoprecipitation of albumin 
Cell lysates were prepared with RIPA buffer containing 1M Tris (pH 7.5), 5M NaCl, 10% NP-
40, 10% deoxycholate and protease cocktail inhibitor. 1mg of cell lysates were incubated with 
100 l of anti-albumin Ab (Abcam)-conjugated Sepharose bead in 500 l PBS at 4 °C forμ μ  
overnight. The Sepharose beads were precipitated at 14,000 rpm for 5 min, and washed with 1 
ml of washing buffer containing 50 mM Tris–Cl and 500 mM NaCl (pH 8.0) for three times. The 
bound complexes were resolved on a 4-12% polyacrylamide gel (Invitrogen), and Coomassie-
stained. 
Protein sequencing using tandem mass spectrometry (MS/MS)
Gel bands were excised and subjected to in-gel digestion and MS/MS. All MS/MS experiments 
were performed using a Nano- LC/MS system consisting of a Surveyor HPLC system and a 7-
tesla Finningan LTQ-FT mass spectrometer (Thermo Electron) equipped with a nano-ESI 
source. For peptide identification, MS/MS spectra were searched using Mascot version 2.0 
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(Matrix Science). Proteins that were identified by one or more high scoring peptides were 
considered to be true matches. The high scoring peptides corresponded to peptides that were 
above the threshold in our Mascot search (expected < 0.05, peptide score > 28). All high scoring 
MS/MS spectra were also manually validated. 
Statistical analysis. Results are presented as mean ±  s.e.m. Two-tailed Student t-tests were used 
for data analysis. A p-value of <0.05 was considered as the criteria of statistical significance.
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Supplementary Table 1. Albumin peptides identified by MS/MS
Protein Observed Charge Mr (expt) Mr(calc) Delta
Peptide
 ion Score
pepide sequence
Human
specific*
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ALB 
(IPI000
22434)
409.5405 3 1225.5996 1225.5978 0.0017 35.55 FKDLGEENFK O
575.3112 2 1148.6078 1148.6077 0.0001 62.83 LVNEVTEFAK X
717.7713 2 1433.528 1433.5261 1.0019 12.15 ETYGEMADCCAK O
566.5943 3 1696.7611 1696.7627 -0.0017 32.7 QEPERNECFLQHK O
464.2504 2 926.4862 926.4861 0.0001 43.7 YLYEIAR X
696.285 3 2085.8333 2085.8302 0.003 49.72
VHTECCHGDLLEC
ADDR 
O
725.3246 2 1442.6379 1442.6347 -0.0001 67.89 YICENQDSISSK O
992.1225 3 2973.3457 2973.3371 0.0085 63.23
SHCIAEVENDEMP
ADLPSLAADFVESK 
O
820.3983 2 1638.782 1638.7751 0.0068 67.62 DVFLGMFLYEYAR O
734.4257 2 1466.8373 1466.8357 0.0011 74.2 RHPDYSVVLLLR O
820.8709 2 1639.7273 1639.7188 0.0085 77.92 QNCELFEQLGEYK O
480.7849 2 959.5553 959.5552 0.0001 42.27 FQNALLVR O
547.3176 3 1638.9287 1638.9304 0.0004 89.2
KVPQVSTPTLVEVS
R 
X
756.4253 2 1510.837 1510.8355 0.0006 76.78 VPQVSTPTLVEVSR X
500.8057 2 999.5983 999.5964 0.0004 57.11 QTALVELVK X
671.8216 2 1341.6303 1341.6274 0.0012 74.67 AVMDDFAAFVEK O
Mr, molecular weight; expt, expected; calc, calculated.
*Human specific peptides (O) are not 100% homologous with bovine peptides, and thus distinguishable 
from their bovine homologues using MS/MS. Non-specific peptides (X) have 100% homology with 
bovine peptides.
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